Drugs / 601
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT05520177 | Dec 2022 → Sep 2024 | occlusion of tributary of retinal vein | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 601 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05520177 ↗ |
| Action | Inhibit | “anti-VEGF” NCT05520177 ↗ |
| Modality | Monoclonal antibody | “recombinant humanized anti-VEGF monoclonal antibody” NCT05520177 ↗ |
| Route | Intravitreal | “Intravitreal injection” NCT05520177 ↗ |